hyperCORE International

Phase 1

Questions?

Phase 1 Capabilities

Nine Phase 1 capable sites in 14 locations in the United States and Canada with 23 Principal Investigators

Collectively conducted 55 Phase 1 trials - 21 were first-in human trials

Overnight capabilities in 8 locations with 107 beds combined. Facilities range from 4,000 to 17,000 SF

On-site pharmacies at 6 sites; PBMC capabilities at 5 sites

Over 2.8 million patients in collective databases; diversity recruitment in Hispanic, Asian, and Black communities

Phase 1 Therapeutics

Ophthalmology
Men’s Health
Oncology
Podiatry
Nutrition
Pulmonology
Immunology
Neurology
Urology
Gastroenterology
Nephrology
Rheumatology
Cannabis & Psychedelics
Devices / Diagnostics
Psychiatry
Hematology
Dermatology Capabilities
Cardiology
Vaccine Capabilities
Pain Management
Smoking Cessation
Gynecology
Endocrinology
Gerontology
NASH Capabilities
Pediatrics
COVID- 19 Capabilities

Phase 1 Testing / Equipment